Obsidian Therapeutics
Expanding the reach of TIL cell therapy
We are a biotechnology company pioneering engineered tumor infiltrating lymphocyte (TIL) cell therapies with the goal of improving outcomes for patients with solid tumor malignancies.
We engineer TIL cell therapies using our proprietary cytoDRiVE® platform technology to express regulatable therapeutic proteins. The resulting cytoTIL cells are designed to improve tolerability and enhance anti-tumor activity.
Follow the inspiring story of Jeff Pipes, a patient diagnosed with metastatic melanoma who participated in a TIL cell therapy clinical trial.
Our therapy remains investigational and in development.
Our Pipeline
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Next-Generation Cellular Therapies Undisclosed
PHASE: Preclinical
OBX-115 Mechanism of Action: Leveraging cytoDRiVE® PLATFORM
Our proprietary cytoDRiVE® platform uses drug-responsive domains (DRDs) to regulate functional protein abundance using an oral, FDA-approved small-molecule drug.
Using cytoDRiVE, a DRD is attached to the identified protein. In the absence of the small-molecule drug (basal state), the fusion protein is unstable and naturally degraded by the cell’s proteasome. Administration of the drug (ON state) stabilizes the protein and enables its expression, allowing protein levels to be regulated in a reversible and dose-dependent manner. In the case of OBX-115, the stabilizing drug is ACZ (acetazolamide, brand name Diamox), and the regulatable protein is membrane-bound IL15 (mbIL15).
Obsidian’s cytoDRiVE Discovery Platform has identified a growing library of internally discovered DRDs of varying sizes and intended purposes, and enables rapid optimization of regulatable and functional proteins in any cell type. We have developed an extensive synthetic biology engineering toolkit that supports the design and optimization of a broad range of therapeutic proteins, including but not limited to type I/II membrane proteins, membrane-bound cytokines, intracellular proteins, secreted proteins, and genome editing proteins.
Engineered TIL Cell Therapy – How it Works
Leveraging cytoDRiVE platform technology, mbIL15 can be regulated using an FDA-approved drug, which allows doctors to increase expression of mbIL15 and boost the function of OBX-115 when needed, and decrease mbIL15 if side effects occur.
